

POSITION STATEMENT

Rimegepant for preventing and treating migraine

Recommendation:

Primary care prescribers are asked to be mindful of the NICE criteria for commencing rimegepant for the prevention **and** treatment of migraine in accordance with NICE TA 906 and NICE TA 919 –
LSCMMG RAG rating Amber 0

It is expected that the Lancashire and South Cumbria management of headache guideline update will be made available to primary care prescribers for further information and guidance later this year.

Background:

The criteria defined by NICE is:

NICE TA 906 - Rimegepant for preventing migraine:

Rimegepant is recommended as an option for **preventing episodic migraine in adults** who have at least 4 and fewer than 15 migraine attacks per month, only if at least 3 preventative treatments have not worked.

NICE TA 919 - Rimegepant for treating migraine:

Rimegepant is recommended as an option for the **acute treatment of migraine with or without aura in adults**, only if for previous migraines:

- at least 2 triptans were tried and they did not work well enough OR
- triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.

Links for further information:

Prevention of migraine:

[NICE TA906 - Rimegepant for preventing migraine](#)

[LSCMMG Rimegepant for preventing migraine](#)

Treatment of migraine:

[NICE TA919 - Rimegepant for treating migraine](#)

[LSCMMG Rimegepant for treating migraine](#)

LSCMMG Primary Care Adult Headache Management Pathway

References

1. National Institute for Health and Care Excellence. NICE TA 906: Rimegepant for preventing migraine. National Institute for Health and Care Excellence, July 2023. Accessed via www.nice.org.uk/ta906 [accessed online 29th January 2024].
2. National Institute for Health and Care Excellence. NICE TA 919: Rimegepant for preventing migraine. National Institute for Health and Care Excellence, October 2023. Accessed via www.nice.org.uk/ta919 [accessed online 29th January 2024].

Please access this guidance via the LMMG website to ensure that the correct version is in use.

Version Control

Version Number	Date	Amendments Made	Author
Version 1.0	February 2024	New document	AGR

©Midlands and Lancashire Commissioning Support Unit, 2024.

The information contained herein may be superseded in due course. All rights reserved.
Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.

Midlands and Lancashire Commissioning Support Unit,
Jubilee House, Lancashire Business Park, Leyland, PR26 6TR
Tel: 01772 644 400 | www.midlandsandlancashirecsu.nhs.uk